Palatin Receives Notice of Non-Compliance from NYSE American PR Newswire CRANBURY, N.J., Oct. 7, 2024...
Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical...
Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results PR Newswire CRANBURY, N.J., Sept. 26, 2024...
Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones PR...
FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye...
First Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads